MediciNova, Inc. — Form 10-Q Summary
Business Context and Reporting Period
MediciNova is a biopharmaceutical company developing small-molecule therapies for serious diseases with unmet medical needs. Its primary programs are MN-166 for progressive multiple sclerosis, ALS and substance dependence, and MN-001 for NASH and idiopathic pulmonary fibrosis. The pipeline also includes MN-221 for acute asthma exacerbations and MN-029 for solid tumors.
This unaudited filing covers the three months ended March 31, 2016, compared with the three months ended March 31, 2015. The company had 32,258,195 common shares outstanding as of April 25, 2016.
Financial Performance and Position
| Metric | Q1 2016 | Q1 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Research, development and patent expense | $1.075 million | $0.720 million |
| General and administrative expense | $2.316 million | $1.495 million |
| Total operating expenses | $3.392 million | $2.215 million |
| Net loss applicable to common stockholders | $3.382 million | $2.215 million |
| Basic and diluted net loss per share | $0.11 | $0.09 |
| Net cash used in operating activities | $2.419 million | $3.234 million |
- Cash and cash equivalents were $27.618 million at March 31, 2016, up from $22.077 million at December 31, 2015. Approximately $27.5 million was held in money market funds.
- Working capital was approximately $27.6 million. Total assets were $43.859 million and total liabilities were $4.718 million at quarter-end.
- Accumulated deficit was $322.809 million. The company had no reported debt financing; liabilities primarily comprised operating payables, deferred tax liability, deferred revenue and lease-related obligations.
- Financing activities provided $7.976 million, primarily from the exercise of 2,131,700 warrants and 129,819 stock options.
- Stock-based compensation was $1.439 million, compared with $0.513 million in the prior-year quarter, materially reducing the cash impact of reported operating expenses.
Material Changes Versus the Prior Comparable Period
- Operating expenses increased 53%, driven by higher stock-based compensation and increased development and administrative activity.
- Research, development and patent expense increased $355,593, or approximately 49%, to $1.075 million. R&D personnel expense and external development expense were the primary categories disclosed as higher.
- General and administrative expense increased $821,027, or approximately 55%, to $2.316 million, primarily because of higher stock-based compensation for performance-based options.
- Net loss increased $1.167 million, or approximately 53%, and loss per share increased from $0.09 to $0.11.
- Despite the larger net loss, operating cash use declined by $814,150, reflecting higher non-cash compensation and changes in working capital.
- Shares used in calculating loss per share increased to 30.4 million from 24.5 million, reflecting equity issuance and exercises.
- Common shares outstanding increased to 32.239 million at March 31, 2016 from 29.956 million at December 31, 2015. Warrants outstanding declined following exercises and expirations.
Guidance, Outlook, Risks and Unusual Items
- Management expected available working capital to fund operations through December 31, 2017, but stated that it could not assure sufficient resources to conduct all planned research and development programs.
- The company expects substantial net losses for the next several years while it continues development activities and potentially expands or acquires programs.
- Management intends to advance programs through investigator-sponsored trials, government or other grants, strategic alliances and potential pharmaceutical partnerships. No revenue was recognized from the Kissei MN-221 services agreement in either comparable quarter; $1.694 million remained as long-term deferred revenue.
- The company may need to raise additional capital depending on clinical development decisions. It also maintains a $30 million at-the-market equity sales agreement, although no shares were sold under it during Q1 2016.
- At March 31, 2016, the company had 5.064 million outstanding stock options and 1.067 million warrants excluded from diluted loss per share because they were anti-dilutive. Subsequent to quarter-end, it received $86,750 from the exercise of 19,466 options.
- The company owns 50% of Zhejiang Sunmy, a Chinese joint venture intended to develop and commercialize MN-221, but no sublicense agreement had been executed. There is no assurance that the sublicense will be completed or that development in China will proceed.
- Key risks include clinical-trial and regulatory failure, limited commercialization history, dependence on external funding and partnerships, future dilution, intellectual-property risks, impairment of goodwill or in-process research and development, and continued operating losses.
- Management reported no material legal proceedings, no material changes to previously disclosed risk factors, and effective disclosure controls as of March 31, 2016.
Most Important Facts for Investors to Verify
- Whether the $27.6 million cash balance and stated funding runway remain adequate relative to planned clinical and operating expenditures.
- Progress, funding sources and trial results for MN-166, MN-001 and other pipeline programs.
- Whether the Kissei research obligations will generate future revenue and when the $1.694 million deferred revenue balance may be recognized.
- Potential dilution from the remaining stock options, warrants and the $30 million at-the-market facility.
- Whether MediciNova can secure strategic partnerships or non-dilutive funding sufficient to advance late-stage development.
- Any changes to the Zhejiang Sunmy sublicense status and the commercial prospects for MN-221 in China.